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RESEARCH
Effects of different regimens to lower blood pressure on
major cardiovascular events in older and younger adults:
meta-analysis of randomised trials
Blood Pressure Lowering Treatment Trialists’ Collaboration
ABSTRACT
Objective Toquantify the relative risk reductions achieved
withdifferent regimens to lower bloodpressure in younger
and older adults.
DesignMeta-analyses and meta-regression analyses
used to compare the effects on the primary outcome
between two age groups (<65 v ≥65 years). Evidence for an
interaction between age and the effects of treatment
sought by fitting age as a continuous variable and
estimating overall effects across trials.
Main outcome measures Primary outcome: total major
cardiovascular events.
Results 31 trials, with 190606 participants, were
included. The meta-analyses showed no clear difference
between age groups in the effects of lowering blood
pressure or any difference between the effects of the drug
classes on major cardiovascular events (all P≥0.24).
Neither was there any significant interaction between age
and treatment when age was fitted as a continuous
variable (all P>0.09). The meta-regressions also showed
nodifference in effects between the twoage groups for the
outcome of major cardiovascular events (<65 v ≥65;
P=0.38).
Conclusions Reduction of blood pressure produces
benefits in younger (<65 years) and older (≥65 years)
adults, with no strong evidence that protection against
major vascular events afforded by different drug classes
varies substantially with age.
INTRODUCTION
Observational studies have shown that blood pressure
levels are strongly and directly related to the relative
risks of stroke andheart disease1 but that the strength of
the association declines with increasing age.2 A recent
large overview found that for each 20 mm Hg lower
usual systolic bloodpressure, the riskof strokewas 33%
lower in those aged 80-89 but 62% lower in those aged
50-59.3 While many trials with broad entry criteria for
age have investigated the effects of lowering blood
pressure on major vascular events, consistently larger
reductions in relative risk have not been reported for
younger participants. This might reflect true compar-
ability of the effects of reducing blood pressure in older
andyoungerpeople butmight alsobe a consequenceof
the limited power of the individual trials to detect
differences in effectiveness between age groups. Like-
wise, there is a paucity of evidence about the effects of
different drug classes in older compared with younger
patients. Some guidelines advocate the selective use of
particular drug regimens based on patients’ age,4 5
though systematic reviews quantifying the compara-
tive effects of regimens on major vascular outcomes
have not been done.
With the global population rapidly ageing6 and
guidelines recommending treatment to lower blood
pressure for an increasing proportion of the elderly
population, we need clear evidence about the effects of
such treatments in older compared with younger
adults. The Blood Pressure Lowering Treatment
Trialists’ Collaboration was established to perform a
prespecified series of overviews of trials investigating
the effects of drugs to lower blood pressure on
cardiovascular mortality and morbidity, including
assessments of the comparative effects of regimens
between major subgroups of patients. We compared
the proportionate risk reductions achieved with
different classes of drugs in younger and older adults.
METHODS
Trials included
Trials were eligible for inclusion if they randomised
patients between a drug to lower blood pressure and
control (placebo or less intensive blood pressure
treatment) or randomised patients between regimens
based on different classes of drug to lower blood
pressure. Trials had to have aminimumof 1000 patient
years of planned follow-up in each randomised group
and must not have presented or published their main
results before we finalised our protocol in July 1995.7
We included in our analyses trials for which data had
been obtained by September 2006. When a trial
includedmore than two treatment arms, we calculated
estimates of effect for all possible comparisons except
when early termination of one arm made such
estimates impossible.8 Data were accepted as data on
individual patients (25 studies) or as tabular data by
using prespecified categories (six studies). The data
requested included participants’ characteristics
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recorded at screening or randomisation, selected
measurements made during follow-up, and details of
the occurrence of all outcomes during the scheduled
follow-up period.
Age groups
The age groups predefined in the original overview
protocol were <65 and ≥65 years at the time of entry
into the trial, henceforth referred to as “younger” and
“older” adults. These cut offs were chosen because
most participating trials used the same categories in
their own subgroup analyses.
Outcomes
Our primary outcome was total major cardiovascular
events, comprising stroke (non-fatal stroke or death
from cerebrovascular disease), coronary heart disease
(non-fatal myocardial infarction or death from cor-
onary heart disease including sudden death) and heart
failure (causing death or resulting in admission to
hospital). Secondary outcomes were stroke, coronary
heart disease, heart failure, cardiovascular death, and
total mortality. All outcomes were prespecified in the
original study protocol.7
Comparisons
The seven comparisons of treatment were those
reported in the second main cycle of overviews9: (a)
angiotensin converting enzyme inhibitor versus pla-
cebo, (b) calcium antagonist versus placebo, (c) more
intensive versus less intensive regimens to lower blood
pressure, (d) angiotensin receptor blocker versus
control regimen, (e) angiotensin converting enzyme
inhibitor versus diuretics/β blockers, (f) calcium
antagonist versus diuretics/β blockers, and (g)
angiotensin converting enzyme inhibitor versus cal-
cium antagonists. Additional comparisons examined
the separate effects of diuretics and β blockers in
different age groups as some recent guidelines have
made specific recommendations about the use of these
treatments in older and younger adults.4 5 These
additional comparisons were (a) angiotensin convert-
ing enzyme inhibitor or calcium antagonist versus β
blockers and (b) angiotensin converting enzyme
inhibitor or calcium antagonist versus diuretics.
Statistical analyses
We calculated the reduction in blood pressure in each
trial arm as the mean of the differences between each
participant’s mean blood pressure during follow-up
and their blood pressure at baseline. We then
calculated the mean difference in blood pressure
between randomised groups by subtracting the values
for the arms compared. Mean levels of baseline
characteristics and the mean difference in blood
pressure between randomised groups were calculated
separately for younger and older adults for each trial.
Overall estimates were obtained by weighting the
estimates from each individual study in proportion to
the number of older and younger adults in that study.
We performed three sets of analyses to explore the
impact of age on the proportional risk reduction
achieved with lowering blood pressure.
Firstly, we carried outmeta-analyses of subgroups of
participantsdefinedaccording to age.For each trial and
each outcome we calculated the relative risk and its
variance separately for each of the two age groups
according to the principle of intention to treat. Each
participant could contribute only the first event in any
category to the calculation for each outcome butmight
contribute an event to analyses of several outcomes.
Overall estimates of effect and 95% confidence inter-
vals were calculated separately for each age group by
using a random effects model and inverse variance
weighting (that is, weighting by the precision of the
estimate for each age group in each trial). The “meta”
routine in STATA (release 9.0; Stata Corporation,
College Station, TX, USA) evaluated effects of
randomised treatments. Consistency of treatment
effects across the age groups was tested with χ2 tests of
homogeneity.
Secondly, we investigated interactions between
treatment to lower blood pressure and age taken as a
continuous variable by fittingCox’s regressionmodels
including treatment, continuous age, and their inter-
action. The regression (“β”) coefficient for the latter
term estimates the log ratio of relative risks, comparing
the treatments, where each relative risk is the effect of a
unit (here taken as 10 years) increase in age with one of
the two treatments.Twenty four trials contributingdata
on individual participants were included in these
analyses, with no comparisons being made for regi-
mens based on angiotensin receptor blockers because
data were available from only one trial.We pooled the
log ratios of relative risks using inverse variance
weighted random effects meta-analysis. The pooled
Angiotensin converting enzyme inhibitor v
placebo
Age <65
Age >65
Calcium antagonist v placebo
Age <65
Age >65
More v less intensive blood pressure
lowering regimen
Age <65
Age >65
0.76 (0.66 to 0.88)
0.83 (0.74 to 0.94)
0.84 (0.54 to 1.31)
0.74 (0.59 to 0.92)
0.88 (0.75 to 1.04)
1.03 (0.85 to 1.24)
0.5 1.0 2.0
813/9514
1251/8005
43/1310
130/2220
212/5024
156/2251
Active
1087/9640
1490/7918
49/1287
170/2134
365/9360
260/4198
Control
No of events/patients
-4.6/-2.1
-4.2/-2.0
-7.2/-2.9
-9.3/-3.8
-3.9/-3.6
-3.3/-3.3
Difference in
SBP/DBP 
(mm Hg)
Favours
active
Favours
control
Risk ratio
(95% CI)
Risk ratio
(95% CI)
0.37
0.59
0.24
P for 
homogeneity
Fig 1 | Comparison of blood pressure lowering regimens against placebo or less intensive control.
SBP/DBP difference=overall difference in mean blood pressure during follow-up between
treatmentgroups (actively treatedgroup versus control group), calculatedbyweightingdifference
observed in each contributing trial by number of individuals in trial. Negative blood pressure
values indicate lower mean follow-up blood pressure in first listed than in second listed groups
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summary was exponentiated to arrive at the overall
estimated ratio of relative risks for a 10 year difference
in age for each outcome.
Thirdly, we carried out meta-regression analyses to
explore the association between the difference in
systolic blood pressure at follow-up between rando-
mised groups and the log relative risk for cardio-
vascular events in each age group. This was
investigated across trials with random effects meta-
regression models with inverse variance weighting.10
Analyses were carried out using themetareg routine in
STATA. We fitted separate regression lines for each
age group and compared the slopes of these lines to test
for adifferential effect of reduction inbloodpressureon
risk reduction between age groups for each outcome.
The model included an interaction term between age
group and systolic blood pressure.10 Assumptions of
linear associations between differences in blood
pressure at follow-up and log relative risks were tested
with standard graphical methods. As trial participants
could contribute only once to a given meta-regression
analysis, for factorial trials that included randomisation
to different intensities of blood pressure lowering and
randomisation to different drug treatmentsw1-w5 we
included only the results of the randomisation to
different intensities of blood pressure lowering. For
similar reasons, trials with randomisation to three
treatment armsw6-w8 contributed results from only two
of the possible three treatment comparisons, with the
control arm participants divided between the two
comparisons. We carried out sensitivity analyses to
examine the impact of removing the three trials that
contributed participants’ data exclusively to older age
groups (≥65 years)w7 w9 w10 and the impact of removing
the six trials for which data on individual participants
were not available.w1 w9 w11-w14 In every analysis P<0.05
indicated that a result was possibly not due to chance,
although each case required careful interpretation,
given the large numbers of comparisons.
RESULTS
Characteristics of trials and patients included
Of the 37 eligible trials,w1-w38 we included 31 (190 606
individuals) in these analyses (see tableAonbmj.com).
For the six remaining trialsw33-w38 we could not extract
data according to criteria specified in the original study
protocol.7 Therewere 96 466 individuals aged<65 and
94 140 aged ≥65 at baseline who contributed to the
primary analyses (table 1). The mean age in the two
groups was 57 and 72 and the proportion of men was
58% and 51%, respectively. Mean baseline blood
pressure was higher in the older age groups, as was
the proportion of primary outcome events that
comprised stroke (table 2).
Meta-analyses of effects of treatments in different age
groups
For the primary outcome, total major cardiovascular
events, in the trials that examined blood pressure
lowering regimens comparedwith placebo or less active
control, there was no evidence of any difference in
reductions in relative risk in different age groups (all
P>0.2 for heterogeneity) (fig 1). Likewise, in the over-
views of trials comparing blood pressure lowering
regimens based on different drug classes there was no
difference in the proportional reductions in total major
cardiovascular events observed between age groups for
any comparison (all P>0.3 for heterogeneity) (figs 2 and
3). While there was some variation in the reductions in
bloodpressurewith the randomised treatments between
age groups, there was no systematic pattern. Among the
35 comparisons between age groups made for the
Table 1 | Mean baseline characteristics and differences in blood pressure at follow-up between randomised groups in subgroups of younger and older adults
Treatment
comparison
Age <65 (n=96 466) Age ≥65 (n=94 140)
Total No
Age
(years)
Baseline SBP/
DBP (mm Hg)
Difference in SBP/DBP
(mm Hg) % Men Total No
Age
(years)
Baseline SBP/
DBP (mm Hg)
Difference in SBP/DBP
(mm Hg) % Men
ACE-I v placebo 19 154 57 137/82 −4.6/−2.1 79 15 923 70 143/80 −4.2/−2.0 72
CA v placebo 2 597 58 149/83 −7.2/−2.9 60 4354 72 168/84 −9.3/−3.8 37
More v less* 15 335 57 165/104 −4.3/−3.5 57 6647 70 173/104 −3.5/−3.4 47
ARB v other 1464 56 151/85 −1.7/−0.3 64 6338 75 163/89 −2.0/−1.2 39
ACE-I v D/BB 22 088 55 153/93 1.3/0.2 54 25 342 73 161/88 2.0/0.5 49
CA v D/BB 43 594 58 154/93 1.1/−0.2 50 46 185 72 157/87 0.5/−0.4 46
ACE-I v CA 10 049 59 145/87 0.9/0.6 55 16 310 73 160/87 1.0/1.0 49
SBP/DBP=systolic/diastolic blood pressure; ACE-I=angiotensin converting enzyme inhibitor; CA=calcium antagonist; ARB=angiotensin receptor blocker; D/BB=diuretic or β blocker.
*More v less intensive blood pressure lowering regimen.
Age <65
Age >65
0.89 (0.75 to 1.05)
0.91 (0.81 to 1.02)
0.5 1.0 2.0
183/742
438/3167
Angiotensin
receptor
blocker
204/722
487/3171
Other
No of events/patients
-1.7/-0.3
-2.0/-1.2
Difference in
SBP/DBP 
(mm Hg)
Favours
angiotensin
receptor
blocker
Favours
other
Risk ratio
(95% CI)
Risk ratio
(95% CI)
0.78
P for 
homogeneity
Fig 2 | Comparison of angiotensin receptor blocker based regimens with control regimens. SBP/
DBP difference=overall difference in mean blood pressure during follow-up between treatment
groups (angiotensin receptor blocker treatedgroupversuscontrol group), calculatedbyweighting
difference observed in each contributing trial by number of individuals in trial. Negative blood
pressure values indicate lower mean follow-up blood pressure in first listed than in second listed
groups
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secondary outcomes there were two with P≤0.05 (www.
thegeorgeinstitute.org/bplttc), and these are likely to
have arisen by chance. Sensitivity analyses in which we
excluded the three trialsw7 w9 w10 that contributed patients
toonlyoneagegroup (≥65years) fromthemeta-analyses
did not make any material difference to the findings.
Similarly, there was no difference in the findings when
we repeated the analyses on the subset of 25 trials for
which data on individual participants were available.
We used data from eight trialsw1 w5 w6 w10 w27-w29 w31 in
subsidiary analyses to examine the separate effects of
regimens based on β blockers and on diuretics
compared with other drug classes (angiotensin con-
verting enzyme inhibitors and calcium antagonist
combined) according to patients’ age. In these ana-
lyses, there was no evidence of a difference in the
proportional risk reduction for major cardiovascular
events between younger and older adults for either
comparison (all P>0.3) (fig 4). We conducted similar
subsidiary analyses to examine the effects of including
eligible trials for which only published data were
available.w36 w38 In these analyses, there was no
evidence of difference between treatment regimens
according to patients’ age (all P>0.22).
Effects of age on blood pressure lowering with age fitted
as continuous variable
We found no evidence of an interaction between age
and the effects of treatment on the primary outcome of
major cardiovascular events for any blood pressure
lowering treatments compared with control (all
P>0.09) (fig 5). The same was true for the comparisons
of different active agents (all P>0.2). For the secondary
outcomes therewasone significant interaction (P=0.02)
among the 30 analyses, and this is most likely to have
arisen by chance (www.thegeorgeinstitute.org/bplttc).
Meta-regressions of effects of blood pressure lowering in
different age groups
There was no difference in the risk reduction achieved
per unit reduction in blood pressure for individuals aged
<65 comparedwith≥65 for theprimaryoutcomeof total
major cardiovascular events (P=0.38) (fig 6) nor for any
of the secondary outcomes (all P≥0.18) (available from
author (www.thegeorgeinstitute.org/bplttc).
DISCUSSION
Principal findings
These analyses provide strong support for the use of
drugs to lower blood pressure in older and younger
adults, with no strong evidence for the selective use of
specific classes of drug according to age. While some
current management guidelines advocate the use of
particular types of drug according to age on the basis of
possible differences in effects on major cardiovascular
events,4 5 11 factors such as tolerability and cost are
probably reasonable bases for choice of drug so long as
effective blood pressure reduction is achieved.12-14 In
particular, for these age groups there was no evidence
of differences between the effects of β blockers and
other classes of drugs in older compared with younger
adults for any outcome studied, and the same was true
for all other drug comparisons.
Findings in context of observational studies
We might expect variation in the effect of lowering
blood pressure because observational data have
shown less strong proportional associations of
blood pressure levels with risk in older compared
with younger adults.3 The analyses prespecified in the
original overview protocol7 identified no attenuation
of risk reductionwith age but were not especially well
powered to detect such effects. Each of the subsidiary
analyses provided better statistical power, and there
were some comparisons that showed evidence of
different effects of blood pressure lowering between
age groups or interactions between age and particular
drug regimens. It is important, however, that the
“statistically significant” subsidiary analyses are
interpreted in light of their post hoc nature, the
multiple comparisons made, and, in the case of the
meta-regressions, the non-randomised nature of the
evaluations. So, our results do not completely
exclude the possibility of differences in the propor-
tional effects of blood pressure lowering regimens
Table 2 | Numbers (percentages) of individualswith stroke,
coronary heart disease, and heart failure by age
Age (years) No Stroke
Coronary heart
disease Heart failure
Age <65 96 466 2096 (2.2) 3624 (3.8) 1030 (1.1)
Age ≥65 94 140 4490 (4.8) 5776 (6.1) 2460 (2.6)
Angiotensin converting enzyme inhibitor v
diuretic or β blocker
Age <65
Age >65
Calcium antagonist v diuretic or β blocker
Age <65
Age >65
Angiotensin converting enzyme inhibitor v
calcium antagonist
Age <65
Age >65
1.05 (0.96 to 1.14)
1.01 (0.95 to 1.06)
1.06 (0.98 to 1.14)
1.02 (0.97 to 1.06)
0.91 (0.78 to 1.06)
0.98 (0.92 to 1.05)
0.5 1.0 2.0
819/9448
1795/10 783
1165/20 358
2653/21 204
548/5130
1583/8170
1st listed
1066/12 012
2525/14 429
1430/23 236
3363/24 981
568/4919
1608/8140
2nd listed
1.3/0.1
2.0/0.5
1.1/-0.2
0.5/-0.4
0.9/0.6
1.0/1.0
Difference in
SBP/DBP 
(mm Hg)
Favours
1st listed
Favours
2nd listed
Risk ratio
(95% CI)
Risk ratio
(95% CI)
0.44
0.38
0.37
P for 
homogeneity
No of events/patients
Fig 3 | Blood pressure lowering regimens based on different drug classes for the outcome total
major cardiovascular events and age groups <65 versus ≥65. SBP/DBP difference=overall
difference in mean blood pressure during follow-up between treatment groups (group assigned
first listed treatment versus group assigned second listed treatment), calculated by weighting
difference observed in each contributing trial by number of individuals in trial. Negative blood
pressure values indicate lower mean follow-up blood pressure in first listed than in second listed
groups
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between age groups but they do suggest that any such
differences are likely to be small.
Clinical implications
As the magnitude of the proportional risk reduction
achieved with blood pressure lowering does not seem to
declinewith age, our findings provide strong support for
the use of blood pressure lowering in elderly people.
Among the older age group there was, in almost every
analysis and for almost every outcome, an estimate of
effect suggesting benefit from blood pressure lowering,
and in no case was there evidence of harm. The much
greater absolute risk in elderly peoplemeans that even if
proportional reductions were attenuated in this group,
the protection afforded would still translate into large
numbers of serious vascular events prevented. These
data also provide considerable reassurance that current
approaches to the use of blood pressure lowering
treatments based on absolute risk, that assume constant
proportional risk reductions across age groups,511-14 are
an appropriate means of quantifying the likely absolute
benefit to be gained from lowering blood pressure.3
Strengths and weaknesses
Our analyses included thousands of major cardio-
vascular events and provided reasonably precise
estimates of the effects of the different regimens in
older and younger adults formost outcomes. They are,
however, subject to several limitations and need to be
interpretedwith these inmind. Firstly, the difference in
mean age between the older and younger participants
was not large—only about 15 years. The observational
data suggest that proportional differences in risk
reduction would be modest for age differences of this
magnitude, and it is possible that these overviews could
have failed to detect real differences in the effectiveness
of blood pressure lowering between age groups. That
said, the analyses with age fitted as a continuous
variable had much better statistical power to detect
interactions between age and treatment to lower blood
pressure and provide reassurance that moderate or
large effects have not been missed. Secondly, because
most patients in the trials fell within a fairly limited age
range, the analyses were unable to define the effects of
blood pressure lowering agents in very elderly people.
Although particular concerns about the safety and
efficacy of treatment to lower blood pressure in this
group have previously been raised,15 recent results
from the HYVET study16 have largely addressed
uncertainty around the benefits of lowering blood
pressure in patients aged ≥80. In the same way that the
limited age range of patients in our analyses could not
define the effects in the very elderly, postulated
differences between the effects of drug regimens in
younger age groups17 cannot be excluded. Thirdly,
although there was reasonable comparability in the
baseline characteristics of younger and older patients it
is possible that different levels of baseline blood
pressure, the proportion of men, and possibly other
comorbiditiesmight have had an effect on the potential
to detect differences between the age groups. Fourthly,
the overviews defined only the short to medium term
effects of the regimens studied and cannot exclude the
evolution of differences between the effects in each age
group in the longer term. Fifthly, the ability of these
analyses to detect differences between regimenswould
have been diminished by incomplete adherence to
Angiotensin converting enzyme inhibitor v placebo
Calcium antagonist v placebo
More v less intensive blood pressure lowering regimen
Angiotensin converting enzyme inhibitor v diuretic or β blocker
Calcium antagonist v diuretic or β blocker
Angiotensin converting enzyme inhibitor v calcium antagonist
1.09 (1.00 to 1.20)
0.90 (0.52 to 1.54)
1.12 (0.91 to 1.37)
0.99 (0.92 to 1.06)
0.95 (0.87 to 1.04)
1.06 (0.98 to 1.15)
0.09
0.70
0.29
0.83
0.25
0.15
0.5 1.0 2.0
1st listed
relatively more
effective in younger
1st listed
relatively more
effective in older
Proportionate increase
in relative risk for
every extra 10 years
of age (95% CI)
Proportionate
increase (95% CI) P value
Fig 5 | Proportionate increase in relative riskofmajor cardiovascular events, first listed v second listed, for every extra10yearsof age
Angiotensin converting enzyme inhibitor or
calcium antagonist v β blocker
Age <65
Age >65
Angiotensin converting enzyme inhibitor or
calcium antagonist v diuretic
Age <65
Age >65
1.03 (0.88 to 1.20)
0.94 (0.84 to 1.06)
1.06 (0.98 to 1.15)
1.03 (0.98 to 1.08)
0.5 1.0 2.0
297/7013
519/6484
923/8447
2412/13 613
308/7058
569/6648
1455/13 683
3786/20 783
0.2/0.1
-0.8/-0.2
1.9/0.0
1.6/0.0
Difference in
SBP/DBP 
(mm Hg)
Favours
1st listed
Favours
2nd listed
Risk ratio
(95% CI)
Risk ratio
(95% CI)
0.38
0.53
P for 
homogeneity
No of events/patients
1st listed 2nd listed
Fig 4 | Regimens based on diuretics and β blockers versus other active agents for total major
cardiovascular events according to age. SBP/DBP difference=overall difference in mean blood
pressure during follow-up between group assigned first listed treatment versus group assigned
diuretic or β blocker, calculated by weighting difference observed in each contributing trial by
numberof individuals in trial.Negativebloodpressurevalues indicate lowermean follow-upblood
pressure in first listed than in second listed groups
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randomised treatments and the extensive use of add-on
therapies. Similarly, the a priori definition of a
“conventional group” that combines two different
drug classes (diuretics and β blockers) represents an
additional challenge, although subsidiary analyses
were not able to detect differences when β blockers
and diuretics were considered separately. Sixthly, data
defined by the prespecified criteria were not available
for all eligible trials, but limited subsidiary analyses
including published data from those studies did not
change the overall study conclusions.
Finally, the primary analyses were based on the
composite outcome of major cardiovascular events,
and this outcome might underestimate any real
difference in the proportional effects of blood pressure
loweringbetweenagegroups.The reason for this is that
the composition of major cardiovascular events varies
between age groups, with the proportion of strokes,
which are more strongly affected by lowering blood
pressure, being larger in the older age groups. This
would tend to inflate themagnitude of the proportional
reduction achieved for major cardiovascular events in
the older compared with the younger group. The
secondary analyses of the separatemajor cause-specific
outcomes do not, however, suggest that this has been a
major cause of confounding.
Conclusions
Our results confirm the benefits of effective control of
blood pressure in older and younger adults. They also
provide substantial reassurance that, within the age
range studied, the benefits of regimens to lower blood
pressure based on different drug classes are largely
comparable across age groups, although there is a
relative paucity of data for those under 50 and over 80.
None the less, these findings should greatly simplify
decision making for millions of clinicians around the
world.
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WHAT IS ALREADY KNOWN ON THIS TOPIC
Inobservational studies theproportional reductions inthe risksofvasculardiseaseassociated
with lower blood pressure levels decline with increasing age, suggesting that the relative
effects of blood pressure lowering drugs might be smaller among elderly people
Some blood pressuremanagement guidelines recommend specific classes of blood pressure
lowering treatment for particular age groups
WHAT THIS STUDY ADDS
Blood pressure reduction produces similar proportional reductions in the risks of vascular
events in younger (<65 years) and older (≥65 years) adults
The absolute benefits of treatment are likely to be particularly large among older individuals
because of their higher average risk
Therewasnoclearevidence tosupport recommendations forparticulardrugclasses inolderor
younger adults
Reduction in risk for each 5 mm Hg reduction in systolic blood pressure:
               Age <65: 11.9% (5.3% to 18.0%) 
               Age >65: 9.1% (3.6% to 14.3%)  
               P for heterogeneity of slopes = 0.38
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Fig 6 | Associations of reduction in blood pressure with risk
reduction for total major cardiovascular events for adults aged
<65 and ≥65. Area of each circle is proportional to inverse
varianceof logodds ratio. Fitted lines representsummarymeta-
regressions for total major cardiovascular events
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